Table 2.
Trial | Antigen: | gp120 | gp120 | gp140 | gp140 | gp41 | gp41 | V1V2 |
---|---|---|---|---|---|---|---|---|
Participants tested/ Isotype: | IgG | IgG3 | IgG | IgG3 | IgG | IgG3 | IgG | |
097-T1 | 55 | 48 | 26 | 48 | 16 | 35 | 17 | |
097-T2 | 18 | 14 | 9 | 14 | 6 | 7 | 5 | |
105-T1 | 25 | 11 | 11 | 5 | ||||
105-T2 | 26 | 18 | 11 | 18 | 15 | 17 | ||
105-T3 | 26 | 18 | 13 | 19 | 16 | 14 | ||
105-T4 | 25 | 22 | 13 | 23 | 21 | 22 | ||
094-T1 | 10 | 9 | 8 | 9 | 8 | |||
094-T2 | 15 | 8 | 13 | 12 | 14 | 12 | 5 | |
094-T3 | 13 | 6 | 5 | 13 | 12 | 13 | 13 | |
205-T1+T3 | 136 | 7 | 16 | 35 | 58 | 32 | 47 | |
205-T4 | 68 | 18 | 7 | 32 | 24 | 31 | 21 |
Number of participants included in each linear model. Blank indicates that trial was not modeled (insufficient positive responses). Participants tested gives the number of participants with measured antibody responses in primary trial, except HVTN 205 which gives number of participants for which our data set contains values.